Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05696613 · ClinicalTrials.gov registry record · Phase 3
A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy
A Phase 3 study of Primary Membranous Nephropathy, sponsored by Cerium Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 148
- Enrollment target
- 20
- Study locations
NCT05696613: Recruiting Phase 3 study of Primary Membranous Nephropathy, sponsored by Cerium Pharmaceuticals.
NCT05696613 is a Phase 3 study of Primary Membranous Nephropathy that is actively recruiting participants, run by Cerium Pharmaceuticals. The registered enrollment target is 148 participants, above the 118-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (25% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05696613, a Phase 3 study of Primary Membranous Nephropathy, is actively recruiting participants, sponsored by Cerium Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 148 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (PMN) at month 24.
Conditions Studied
Interventions
- DRUG Rituximab
- DRUG SNP-ACTH (1-39) Gel
Study Locations (20)
Florida
- RecioMed Clinical Research Network, Inc. - Boynton Beach
- South Florida Nephrology Research - Coral Springs
- Therafirst Medical Center - Fort Lauderdale
- Reliant Medical Research, LLC - Miami
- Vista Health Research, LLC - Miami
- Genesis Clinical Research - Tampa
California
- Academic Medical Research Institute - Los Angeles
- North America Research Institute - San Dimas
- Valiance Clinical Research - Tarzana
Georgia
- Fides Clinical Research - Atlanta
- Costal Medical Research - Brunswick
Texas
- Prolato Clinical Research Center - Houston
- P&I Clinical Research LLC - Lufkin
Virginia
- University of Virginia - Charlottesville
- Nephrology Associates of Northern Virginia - Fairfax
Illinois
- Insight Hospital and Medical Center Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Michigan
- Center for Advanced Kidney Research, PLC - Saint Clair Shores
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2023-03-13 |
| Est. Completion | 2026-03-01 |
| Phase | Phase 3 |
What NCT05696613 shows while recruiting
NCT05696613 is an interventional study that assigns participants to a tested intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap, above the 118-participant average among 8 other Primary Membranous Nephropathy trials with a reported enrollment target (25% higher).
The record links to 1 condition, with Primary Membranous Nephropathy appearing as the primary indexed condition, and to 2 interventions - of which Rituximab is the first listed.
NCT05696613 names 20 study sites across 10 states, led by Florida, California, Georgia.
Frequently Asked Questions
What is clinical trial NCT05696613 about?
NCT05696613 is a clinical study titled "A Study of SNP-ACTH (1-39) Gel in Patients With Primary Membranous Nephropathy". The goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membranous nephropathy (P...
What is the current status of trial NCT05696613?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 148 participants. The study started on 2023-03-13. Estimated completion is 2026-03-01.
What conditions does trial NCT05696613 study?
This clinical trial studies the following conditions: Primary Membranous Nephropathy.
What interventions are being tested in trial NCT05696613?
The interventions under investigation include: Rituximab (DRUG), SNP-ACTH (1-39) Gel (DRUG).
Who is sponsoring clinical trial NCT05696613?
This trial is sponsored by Cerium Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05696613 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Membranous Nephropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05696613's enrollment target sits among peer trials
148 4th of 8 higher than 5 of 8 other Primary Membranous Nephropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Primary Membranous Nephropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Learn More About the Effects and Safety of Felzartamab Infusions in Adults With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 3
-
A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
ACTIVE NOT RECRUITING · Phase 3
-
Study of WAL0921 in Patients With Glomerular Kidney Diseases
RECRUITING · Phase 2
-
A Phase 2 Study of Budoprutug in Subjects With Primary Membranous Nephropathy
RECRUITING · Phase 2
-
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
RECRUITING · Phase 2
-
A Study to Evaluate Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI